Sangamo Therapeutics (LTS:0R1D) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1D Sangamo Therapeutics Inc LTS:0R1D
41 GF Score
Price $0.14
GF Value $12.39
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Sangamo Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0R1D
41GF Score
Sangamo Therapeutics Inc LTS:0R1D
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.14 is trading 98.9% below its estimated GF Value™ of $12.39. GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0R1D:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $12.39 vs. price of $0.14 (98.9% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USAGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc. is a clinical-stage genomic medicine company based in the United States. It develops engineered zinc finger proteins and other gene-editing and gene-regulation technologies to create treatments for serious genetic and neurological diseases. Its pipeline spans epigenetic regulation therapies, engineered adeno-associated virus (AAV) capsids for targeted delivery to the central nervous system, and gene therapies for conditions such as Fabry disease, hemophilia A, and neurological disorders including prion disease, tauopathies, ALS/FTD, and Huntington's disease. Sangamo also pursues ex vivo cell therapy programs, including CAR-Treg approaches for autoimmune and inflammatory conditions. The company generates revenue primarily through collaboration and license agreements with pharmaceutical partners, including milestone payments and royalties, alongside research funding, rather than from marketed products, as it has no approved medicines. Its activities are concentrated in the United States, with partnerships extending to international biopharmaceutical collaborators.
41GF Score

Get the complete analysis for LTS:0R1D

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$12.39
GF Value